BNP Paribas Asset Management
IMVT icon

BNP Paribas Asset Management’s Immunovant IMVT Stock Holding History

BNP Paribas Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.1K Buy
1,333
+508
+62% +$13.2K ﹤0.01% 1876
2025
Q4 		$21K Buy
825
+351
+74% +$7.83K ﹤0.01% 1945
2025
Q3 		$8K Hold
474
– – ﹤0.01% 1697
2025
Q2 		$8K Buy
+474
New +$7.17K ﹤0.01% 1850

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BNP Paribas Asset Management's IMVT Position: Q1 2026 in Review

BNP Paribas Asset Management increased its Immunovant (IMVT) stake by 62% in Q1 2026, buying an estimated $13.2K and bringing the position to 1,333 shares worth $33.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1876.

BNP Paribas Asset Management first reported a position in IMVT in Q2 2025 and has held it in 4 quarters since. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • BNP Paribas Asset Management held 1,333 shares of Immunovant worth $33.1K as of Q1 2026.
  • BNP Paribas Asset Management bought 508 Immunovant shares in Q1 2026, an estimated $13.2K.
  • Immunovant made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #1876 holding.
  • BNP Paribas Asset Management first reported a position in Immunovant in Q2 2025 and has held it in 4 quarters since.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.